Can BMS parlay its surprise 'win and a miss' in first-line lung cancer into a net gain? - FiercePharma

Can BMS parlay its surprise 'win and a miss' in first-line lung cancer into a net gain?  FiercePharma

If you thought you knew what was coming in Bristol-Myers Squibb's CheckMate-227 trial, forget it. The company's star immunotherapy Opdivo won one segment ...